Stephan Christgau

Board of Directors
Ophthalmology
Adenium Biotech
Denmark

Doctor Ophthalmology
Biography

 Prior to joining Novo Seeds, Dr Christgau was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment. He also played an active role in the company’s financing including a public listing in the USA on the OTC exchange through a reverse merger with a public shell company. Previously Dr Christgau worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S. Dr Christgau is the author of more than 60 scientific publications and inventor on more than 30 patent families. Dr Christgau serves on the board of directors of EpiTherapeutics ApS and Inagen ApS, both Danish based biotech companies.

Research Intrest

 Ophthalmology